NYSEARCA:PPH - Market Vectors Pharmaceutical ETF Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$60.3799 0.00 (0.00 %)
(As of 07/20/2018 10:07 AM ET)
Previous Close$60.38
Today's Range$60.23 - $60.3799
52-Week Range$53.83 - $64.65
Volume426 shs
Average Volume91,445 shs
Market Capitalization$354.64 million
P/E RatioN/A
Dividend Yield1.68%
Beta0.85

Receive PPH News and Ratings via Email

Sign-up to receive the latest news and ratings for PPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEARCA
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEARCA:PPH
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares4,638,000
Market Cap$354.64

Market Vectors Pharmaceutical ETF (NYSEARCA:PPH) Frequently Asked Questions

What is Market Vectors Pharmaceutical ETF's stock symbol?

Market Vectors Pharmaceutical ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "PPH."

How often does Market Vectors Pharmaceutical ETF pay dividends? What is the dividend yield for Market Vectors Pharmaceutical ETF?

Market Vectors Pharmaceutical ETF declared a quarterly dividend on Monday, July 2nd. Stockholders of record on Tuesday, July 3rd will be paid a dividend of $0.2493 per share on Monday, July 9th. This represents a $1.00 annualized dividend and a dividend yield of 1.65%. The ex-dividend date is Monday, July 2nd. View Market Vectors Pharmaceutical ETF's Dividend History.

What is the consensus analysts' recommendation for Market Vectors Pharmaceutical ETF?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Market Vectors Pharmaceutical ETF in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has Market Vectors Pharmaceutical ETF been receiving favorable news coverage?

Headlines about PPH stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Market Vectors Pharmaceutical ETF earned a news sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the company an impact score of 45.13 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Market Vectors Pharmaceutical ETF?

Shares of PPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Market Vectors Pharmaceutical ETF's stock price today?

One share of PPH stock can currently be purchased for approximately $60.3799.

How big of a company is Market Vectors Pharmaceutical ETF?

Market Vectors Pharmaceutical ETF has a market capitalization of $354.64 million.


MarketBeat Community Rating for Market Vectors Pharmaceutical ETF (NYSEARCA PPH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  15 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  31
MarketBeat's community ratings are surveys of what our community members think about Market Vectors Pharmaceutical ETF and other stocks. Vote "Outperform" if you believe PPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.